Melbourne-based Telix Pharmaceuticals Ltd (ASX:TLX) is set to expand its manufacturing and distribution footprint in North America with the acquisition of RLS Inc – the only US radiopharmacy network which is Joint Commission-accredited. The two companies have entered an agreement for Telix to take on RLS Inc from its parent company, RLS Group Ltd, in a move which will increase the former’s manufacturing footprint in North America, establishing a future radiometal production network to benefit the company and its strategic partners. RLS holds 31 licensed radiopharmacies in major cities across t…